

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/798,096	10/798,096 03/11/2004		Rea-Min Chu	P/741-176	6503
2352	52 7590 05/18/2006			EXAMINER	
OSTROLENK FABER GERB & SOFFEN 1180 AVENUE OF THE AMERICAS NEW YORK, NY 100368403				LIETO, LOUIS D	
				ART UNIT	PAPER NUMBER
	,			1632	
			DATE MAILED: 05/18/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

Legal Instruments Examiner (LIE), if applicable
U.S. Patent and Trademark Office

PTOL-324 (01-06)

amendment.

Failure to timely respond to this notice will result in:

filed in response to a Quayle action; or

Part of Paper No. 20060505

Telephone No.

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment

Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental

Continuation of 4(e) Other: Applicant originally elected the invention of to a complex immuno-gene medical composition for inhibiting tumor cells, comprising DNA Sequences SEQ ID NO 1 and SEQ ID NO 2, and a method of using the composition to inhibit the growth of tumor cells, and CTVT as the species of tumor cells and muscle electroporation as the species of plasmid administration, in the reply filed on 7/28/2005. In the reply of 2/21/2006, applicant has cancelled all of the outstanding claims and replaced them with new claims drawn to a complex immuno-gene medical composition for inhibiting tumor cells, comprising DNA Sequences SEQ ID NO 1 and SEQ ID NO 3, and a method of using the composition to inhibit the growth of tumor cells. Applicant's new claims are drawn to subject matter that is different from that originally elected. These new claims are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: SEQ ID NO:2 and SEQ ID NO:3 differ in structure and sequence, and thus represent patentably distinct subject matter. Accordingly, the newly provided claims are non-compliant since they are directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

DEBORAH CROUCH PRIMARY EXAMINER GROUP 1800/630

Deveral Crond